Health Canada is requesting Canadian manufacturers to temporarily discontinue distribution of Ranitidine products (common trade name: ZANTAC®) while they investigate the potential presence of an impurity called NDMA (N-nitrosodimethylamine). NDMA is classified as a probable human carcinogen, which means long-term exposure to levels above what is considered safe could increase the risk of cancer.
Products currently available in pharmacies may continue to be distributed.
Health Canada recommends that patients talk to their health care team about alternative treatment options.
For more information, click here.